Iroko Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Iroko Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013996
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Iroko Pharmaceuticals LLC (Iroko) is a specialty pharmaceutical company that develops and commercializes pharmaceutical products. The company’s products comprise low dose Nonsteroidal anti-inflammatory drugs such as meloxicam, indomethacin, and diclofenac that are in various stages of nonclinical and clinical development. It offers products in capsules and tablets dosage forms. Iroko utilizes SoluMatrix fine particle technology to produce NSAIDs as submicron particles. The company focuses its research in advancing the science of analgesia in the areas of pain management. It markets its products through sales and distribution networks located across the globe. Iroko is headquartered in Philadelphia, Pennsylvania, the US.

Iroko Pharmaceuticals LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Iroko Pharma To Raise US$75 Million In Venture Financing 10
Licensing Agreements 11
Iroko Pharma Enters into Licensing Agreement with Laboratorios Saval 11
Iroko Pharma Enters into Licensing Agreement with Litha Pharma for ZORVOLEX 12
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 13
Iroko Pharma Enters into Licensing Agreement with Landsteiner Scientific for Zorvolex 14
Iroko Pharma Enters into Licensing Agreement with Calox for Zorvolex 15
Iroko Pharma Enters into Licensing Agreement with EMS for Zorvolex 16
Iroko Pharma Enters Licensing Agreement With Algorithm For Zorvolex Capsules 17
Iroko Pharma Enters Licensing Agreement With Fahrenheit For Zorvolex Capsules 18
Equity Offering 19
Iroko Pharma Withdraws IPO Of Shares For Up To US$145 Million 19
Asset Transactions 21
Merus Labs Acquires Canadian Rights Of Vancocin From Iroko International 21
Acquisition 22
Iroko Pharma Acquires iCeutica 22
Iroko Pharmaceuticals LLC – Key Competitors 23
Iroko Pharmaceuticals LLC – Key Employees 24
Iroko Pharmaceuticals LLC – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Corporate Communications 26
Jul 11, 2016: Iroko Pharmaceuticals Appoints Louis J. Vollmer as President and Chief Executive Officer 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Iroko Pharmaceuticals LLC, Deals By Therapy Area, 2011 to YTD 2017 8
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Iroko Pharma To Raise US$75 Million In Venture Financing 10
Iroko Pharma Enters into Licensing Agreement with Laboratorios Saval 11
Iroko Pharma Enters into Licensing Agreement with Litha Pharma for ZORVOLEX 12
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 13
Iroko Pharma Enters into Licensing Agreement with Landsteiner Scientific for Zorvolex 14
Iroko Pharma Enters into Licensing Agreement with Calox for Zorvolex 15
Iroko Pharma Enters into Licensing Agreement with EMS for Zorvolex 16
Iroko Pharma Enters Licensing Agreement With Algorithm For Zorvolex Capsules 17
Iroko Pharma Enters Licensing Agreement With Fahrenheit For Zorvolex Capsules 18
Iroko Pharma Withdraws IPO Of Shares For Up To US$145 Million 19
Merus Labs Acquires Canadian Rights Of Vancocin From Iroko International 21
Iroko Pharma Acquires iCeutica 22
Iroko Pharmaceuticals LLC, Key Competitors 23
Iroko Pharmaceuticals LLC, Key Employees 24

★海外企業調査レポート[Iroko Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lavendon Group Plc:企業の戦略・SWOT・財務情報
    Lavendon Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lavendon Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Brainsway Ltd (BRIN):企業の財務・戦略的SWOT分析
    Summary Brainsway Ltd (Brainsway) is a medical device company that develops and markets transcranial magnetic stimulation systems and noninvasive medical device for treatment of neurological and psychopathological disorders. The company provides deep transcranial magnetic stimulation products. It of …
  • Poudre Valley Rural Electric Association, Inc.:発電所・企業SWOT分析
    Poudre Valley Rural Electric Association, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, i …
  • Repsol, S.A.:企業の戦略・SWOT・財務分析
    Repsol, S.A. - Strategy, SWOT and Corporate Finance Report Summary Repsol, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Royal Mail plc (RMG):企業の財務・戦略的SWOT分析
    Royal Mail plc (RMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Boart Longyear Ltd:企業の戦略・SWOT・財務情報
    Boart Longyear Ltd - Strategy, SWOT and Corporate Finance Report Summary Boart Longyear Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • MannKind Corp (MNKD):医療機器:M&Aディール及び事業提携情報
    Summary MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a US FDA approved rapid-action inhaled insulin used to control high …
  • Asn Bank
    Asn Bank - Strategy, SWOT and Corporate Finance Report Summary Asn Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Otonomy Inc (OTIC):製薬・医療:M&Aディール及び事業提携情報
    Summary Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company’s Otiprio is the US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses Otividex for …
  • Shionogi Inc:企業の戦略的SWOT分析
    Shionogi Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Thai Beverage Public Company Limited:戦略・SWOT・企業財務分析
    Thai Beverage Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Thai Beverage Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Oncternal Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Oncternal Therapeutics Inc (Oncternal), formerly Tokalas, Inc., is a clinical-stage oncology company which focuses on the development of therapies for rare and common cancers. Its pipeline compound portfolio includes cirmtuzumab and TK216. The company’s pipeline compounds are primarily focus …
  • National Australia Bank Limited:企業の戦略・SWOT・財務情報
    National Australia Bank Limited - Strategy, SWOT and Corporate Finance Report Summary National Australia Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Kanematsu Electronics Ltd (8096):企業の財務・戦略的SWOT分析
    Kanematsu Electronics Ltd (8096) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • CenterPoint Energy Inc (CNP):電力:M&Aディール及び事業提携情報
    Summary CenterPoint Energy Inc (CenterPoint) is an energy utility company that carries out electric transmission and distribution, and natural gas distribution. It is also involved in natural gas sales and service, pipeline services and other field services. The company sells regulated intrastate na …
  • Shin-Etsu Chemical Co., Ltd.:企業の戦略・SWOT・財務分析
    Shin-Etsu Chemical Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shin-Etsu Chemical Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Sun Pharma Advanced Research Company Ltd (SPARC)-製薬・医療分野:企業M&A・提携分析
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd is a pharma research and drug discovery company that conducts research and and produces drugs. The company develops active pharmaceutical ingredients, formulations and drug delivery technologi …
  • Ingram Micro Inc.:企業の戦略的SWOT分析
    Ingram Micro Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • vTv Therapeutics Inc (VTVT):企業の財務・戦略的SWOT分析
    Summary vTv Therapeutics Inc (vTv), formerly TransTech Inc, is a pharmaceutical company that discovers, develops and commercializes human therapeutics. The company offers a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases includ …
  • Welltec AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Welltec AS (Welltec) is an oil and gas service provider that develops and offers well technologies and solutions for the oil and gas industries. The company's solutions include wireline services, milling solutions, robotic well solutions, conveyance solutions, clean-out solutions, and mechan …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆